ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Performance Based

<< Previous

Bullboard Posts

Next >>

Post by goldtechon May 17, 2024 1:05pm

160 Views

Post# 36045806

Performance Based

So this Board wants more option shares as the price goes lower!!!!!! This passive rubber stamp Board does nothing in the way of creating any value for the company whatsoever and only think of themselves. As long as they have the decision making for Promis the Company will continue to be lathargic.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments